FI925255L - Aromatiska amino-alkoholderivat med egenskaper som motverkar sockersjuka och fetma, deras framstaellning och terapeutiska anvaendningar - Google Patents

Aromatiska amino-alkoholderivat med egenskaper som motverkar sockersjuka och fetma, deras framstaellning och terapeutiska anvaendningar Download PDF

Info

Publication number
FI925255L
FI925255L FI925255A FI925255A FI925255L FI 925255 L FI925255 L FI 925255L FI 925255 A FI925255 A FI 925255A FI 925255 A FI925255 A FI 925255A FI 925255 L FI925255 L FI 925255L
Authority
FI
Finland
Prior art keywords
och
sockersjuka
motverkar
fetma
aromatiska
Prior art date
Application number
FI925255A
Other languages
English (en)
Finnish (fi)
Other versions
FI925255A7 (fi
FI925255A0 (fi
Inventor
Takashi Fujita
Takao Yoshioka
Hiroyoshi Horikoshi
Shinji Yoshioka
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of FI925255A0 publication Critical patent/FI925255A0/fi
Publication of FI925255A7 publication Critical patent/FI925255A7/fi
Publication of FI925255L publication Critical patent/FI925255L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FI925255A 1991-11-20 1992-11-19 Aromatiska amino-alkoholderivat med egenskaper som motverkar sockersjuka och fetma, deras framstaellning och terapeutiska anvaendningar FI925255L (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP30458191 1991-11-20

Publications (3)

Publication Number Publication Date
FI925255A0 FI925255A0 (fi) 1992-11-19
FI925255A7 FI925255A7 (fi) 1993-05-21
FI925255L true FI925255L (fi) 1993-05-21

Family

ID=17934718

Family Applications (1)

Application Number Title Priority Date Filing Date
FI925255A FI925255L (fi) 1991-11-20 1992-11-19 Aromatiska amino-alkoholderivat med egenskaper som motverkar sockersjuka och fetma, deras framstaellning och terapeutiska anvaendningar

Country Status (23)

Country Link
US (3) US5977374A (enExample)
EP (1) EP0543662B1 (enExample)
JP (2) JP2654323B2 (enExample)
KR (1) KR0149679B1 (enExample)
CN (3) CN1034497C (enExample)
AT (1) ATE143002T1 (enExample)
AU (2) AU655689B2 (enExample)
CA (1) CA2083323A1 (enExample)
CZ (2) CZ280820B6 (enExample)
DE (1) DE69213892T2 (enExample)
DK (1) DK0543662T3 (enExample)
ES (1) ES2094308T3 (enExample)
FI (1) FI925255L (enExample)
GR (1) GR3021245T3 (enExample)
HK (1) HK218496A (enExample)
HU (1) HUT66816A (enExample)
IL (3) IL103825A (enExample)
MX (1) MX9206740A (enExample)
NO (1) NO179246C (enExample)
NZ (1) NZ245188A (enExample)
RU (2) RU2095344C1 (enExample)
TW (2) TW290543B (enExample)
ZA (1) ZA928960B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0915090A1 (en) * 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
GB9313574D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Medicaments
CA2145257A1 (en) * 1994-03-23 1995-09-24 Takashi Fujita Thiazolidine and oxazolidine derivatives, their preparation and their medical use
CA2146701A1 (en) * 1994-04-11 1995-10-12 Takashi Fujita Heterocyclic compounds having anti-diabetic activity, their preparation and their use
WO1995033724A1 (en) * 1994-06-09 1995-12-14 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9525177D0 (en) * 1995-12-08 1996-02-07 Glaxo Group Ltd Chemical compounds
GB9525121D0 (en) * 1995-12-08 1996-02-07 Glaxo Group Ltd Chemical compounds
EP0783888A1 (en) 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
DE69625795T2 (de) * 1996-04-09 2003-08-14 Dr. Reddy's Laboratories Ltd., Hyderabad Thiazolidinedionderivate mit antidiabetischen, hypolipidämischen und antihypertensiven Eigenschaften, Verfahren zu deren Herstellung und pharmazeutischen Zusammenstellungen, die sie enthalten
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
KR100579765B1 (ko) * 1996-07-01 2006-12-28 닥터 레디스 레보러터리즈 리미티드 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
US5990169A (en) * 1996-10-23 1999-11-23 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
GB9706707D0 (en) * 1997-04-02 1997-05-21 Glaxo Group Ltd Chemical compounds
JPH10338679A (ja) * 1997-04-08 1998-12-22 Mitsubishi Rayon Co Ltd チアゾリジン誘導体の製造方法
HUP9702411A2 (hu) * 1997-12-11 2000-03-28 Gyógyszerkutató Intézet Kft. Fenoxi-alkil-amin-származékok és a vegyületeket tartalmazó antiaritmiás hatású gyógyszerkészítmények
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US6006419A (en) * 1998-09-01 1999-12-28 Millitech Corporation Synthetic resin transreflector and method of making same
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
GB9929297D0 (en) * 1999-12-11 2000-02-02 Glaxo Group Ltd Process
SK14922002A3 (sk) * 2000-03-17 2003-04-01 Ajinomoto Co., Inc. Farmaceutický prostriedok na prevenciu, zlepšenie a/alebo liečenie diabetickej komplikácie a použitie postprandiálnej látky na zníženie hladiny krvného cukru
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
SK152003A3 (en) * 2000-07-13 2004-07-07 Sankyo Co Amino alcohol derivatives
AU2001292161A1 (en) * 2000-10-20 2002-04-29 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
US7709677B2 (en) 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
WO2002081426A1 (en) * 2001-04-05 2002-10-17 Smithkline Beecham Corporation Peptide deformylase inhibitors
TWI311133B (en) * 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
WO2003010157A1 (en) * 2001-07-23 2003-02-06 Dr. Reddy's Research Foundation Dioxane derivatives and a process for their preparation
JPWO2003016265A1 (ja) 2001-08-17 2004-12-02 エーザイ株式会社 環状化合物およびｐｐａｒアゴニスト
EP1478625A1 (en) 2002-02-27 2004-11-24 Pfizer Products Inc. Processes and intermediates useful in preparing beta-3-adrenergic receptor agonists
WO2003072573A1 (en) 2002-02-27 2003-09-04 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
DOP2003000587A (es) * 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
MXPA06007173A (es) * 2003-12-23 2006-08-23 Astellas Pharma Inc Derivados de aminoalcohol.
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
EP1891971A4 (en) * 2005-01-31 2010-02-03 Ajinomoto Kk MEDICAL COMPOSITION USING HYPERGLY CRAB MEDICAMENT TO TREAT OR TREAT GLUCOSE-INTOLERANCE, BORDERLINE DIABETES, INSULIN RESISTANCE AND HYPERINSULINEMIA
ES2265276B1 (es) * 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2009052693A1 (fr) 2007-10-24 2009-04-30 Zhu, Xiaoying Dispositif d'écran à enroulement
AU2008318293B2 (en) * 2007-11-01 2014-07-31 Howard Florey Institute Aryloxy amine compounds and their use as sodium channel modulators
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
US9968531B2 (en) 2015-08-05 2018-05-15 Dupont Tate & Lyle Bio Products Company, Llc Deodorants containing 1,3-propanediol
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
US12065394B2 (en) 2018-03-26 2024-08-20 Seoul National University R&DBFoundation Compound and pharmaceutical composition for preventing or treating obesity or metabolic syndrome comprising thereof
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3976783A (en) * 1970-07-18 1976-08-24 Pfizer Inc. Method of stimulating the heart employing ureido substituted phenyl-alkanolamine, alkylamine and α-aminoalkyl ketone derivatives
GB1551260A (en) * 1976-02-09 1979-08-30 Allen & Hanburys Ltd Phenylethanolamine derivatives
DE2965655D1 (en) * 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
EP0023385B1 (en) * 1979-06-16 1982-12-15 Beecham Group Plc Ethanamine derivatives, their preparation and use in pharmaceutical compositions
ATE1899T1 (de) * 1979-06-16 1982-12-15 Beecham Group Plc Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
DE3062216D1 (en) * 1979-09-06 1983-04-07 Beecham Group Plc Cinnamic acid derivatives, their preparation, and pharmaceutical compositions containing them
DE3368258D1 (en) * 1982-07-16 1987-01-22 Beecham Group Plc 2-aminoethyl ether derivatives, processes for their preparation and pharmaceutical compositions containing them
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
GB8620951D0 (en) * 1986-08-29 1986-10-08 Beecham Group Plc Compounds
DE10199003I1 (de) * 1987-09-04 2003-06-12 Beecham Group Plc Substituierte Thiazolidinionderivate
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
GB8910374D0 (en) * 1989-05-05 1989-06-21 Ici Plc Chemical compounds
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
GB9111426D0 (en) * 1991-05-28 1991-07-17 Ici Plc Chemical compounds
US5508296A (en) * 1991-07-30 1996-04-16 Yamanouchi Pharmaceutical Co., Ltd. Bisheterocyclic derivative or salt thereof
GB9313574D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
CN1033750C (zh) 1997-01-08
AU7751894A (en) 1995-01-12
EP0543662A3 (en) 1993-08-11
DE69213892T2 (de) 1997-04-17
KR0149679B1 (ko) 1998-10-15
HUT66816A (en) 1995-01-30
EP0543662A2 (en) 1993-05-26
FI925255A7 (fi) 1993-05-21
NO179246C (no) 1996-09-04
NZ245188A (en) 1994-07-26
FI925255A0 (fi) 1992-11-19
HK218496A (en) 1996-12-27
AU670007B2 (en) 1996-06-27
HU9203638D0 (en) 1993-01-28
IL103825A (en) 1998-04-05
NO924440D0 (no) 1992-11-18
RU2095344C1 (ru) 1997-11-10
KR930009982A (ko) 1993-06-21
RU94036004A (ru) 1996-07-10
ZA928960B (en) 1993-05-19
GR3021245T3 (en) 1997-01-31
TW290543B (enExample) 1996-11-11
NO179246B (no) 1996-05-28
DK0543662T3 (enExample) 1997-03-03
AU2849392A (en) 1993-05-27
DE69213892D1 (de) 1996-10-24
CZ280328B6 (cs) 1995-12-13
ATE143002T1 (de) 1996-10-15
CN1073428A (zh) 1993-06-23
IL103825A0 (en) 1993-04-04
CN1054846C (zh) 2000-07-26
TW233294B (enExample) 1994-11-01
ES2094308T3 (es) 1997-01-16
MX9206740A (es) 1993-05-31
NO924440L (no) 1993-05-21
AU655689B2 (en) 1995-01-05
CN1034497C (zh) 1997-04-09
US5635534A (en) 1997-06-03
CZ34595A3 (en) 1996-04-17
IL110804A (en) 1997-07-13
JP2991985B2 (ja) 1999-12-20
JPH09188669A (ja) 1997-07-22
CN1106396A (zh) 1995-08-09
CN1151401A (zh) 1997-06-11
RU2081113C1 (ru) 1997-06-10
US5576340A (en) 1996-11-19
JP2654323B2 (ja) 1997-09-17
JPH0625118A (ja) 1994-02-01
CZ343692A3 (en) 1993-12-15
CZ280820B6 (cs) 1996-04-17
IL110804A0 (en) 1994-11-11
EP0543662B1 (en) 1996-09-18
CA2083323A1 (en) 1993-05-21
US5977374A (en) 1999-11-02

Similar Documents

Publication Publication Date Title
FI925255L (fi) Aromatiska amino-alkoholderivat med egenskaper som motverkar sockersjuka och fetma, deras framstaellning och terapeutiska anvaendningar
FI925735L (fi) Polymerer och oligomerer av gallsyraderivat, foerfarande foer deras framstaellning och deras anvaendning som laekemedel
FI935795L (fi) Ctl4a-receptor, fusionsproteiner innehaollande denna och anvaendningar daerav
FI923337L (fi) Organiska fluorenylmetallfoereningar, framstaellning och anvaendning daerav
FI922977L (fi) Heterocykliska foereningar, deras framstaellning och anvaendning
FI923366L (fi) 5-lediga heterocykler, foerfarande foer deras framstaellning och dessa foereningar innehaollande laekemedel
FI923960L (fi) 5-ledad heterocykler, foerfarande foer deras framstaellning och dessa foereningar innehaollande laekemedel
FI921030L (fi) Cykliska ureaderivat, dessa foereningar innehaollande laekemedel och foerfarande foer deras framstaellning
FI923691L (fi) Cykliska iminoderivat, dessa foereningar innehaollande farmaceutiska blandningar och foerfarande foer deras framstaellning
FI932961L (fi) Metallocener med arylsubsituerade indenylderivat som ligander, foerfarande foer framstaellning av dessa och anvaendning av dessa som katalysatorer
FI923223A7 (fi) Alkenylgrupper omfattande siloxankopolymerer, deras framstaellning och anvaendning
FI924687L (fi) Heterobiarylderivat, dessa foereningar innehaollande laekemedel och foerfarande foer deras framstaellning
FI923775L (fi) 2-piperazinonfoereningar, deras framstaellning och anvaendning
FI934426L (fi) Tiazolidindionderivat, framstaellning och anvaendning daerav
FI933802A7 (fi) Oxazolidinderivat med egenskaper som motverkar sockersjuka och fetma, deras framstaellning och deras terapeutiska anvaendningar
FI925926L (fi) Sammansaettning som innehaoller hydrerade sackarider med laog kariesframkallande effekt, foerfarande foer framstaellning av dessa och tillaempningen av denna sammansaettning
FI945662A0 (fi) Roerformad stomme, i synnerhet som hylselement och med hylselement foersedd stomme
FI924084L (fi) Tramadol-n-oxidmaterial, enantiomerer och kompositioner daerav och deras anvaendning
FI923947A7 (fi) Foerfarande foer pulsbreddsmodulation foer oekad linearitet, minskad kommutationsfoerlust och oekad utspaenning i en vaexelriktare/omriktare
FI921049L (fi) Hydrazonderivat, deras framstaellning och anvaendning
FI922875L (fi) Foereningar med reninhaemmande egenskaper, foerfarande foer deras framstaellning och deras anvaendning
FI913201A7 (fi) Ymppolysackarider, deras framställningsförfarande och deras användning som sekvesteringsagenter
FI925501L (fi) Imidazolfoereningar, deras framstaellning och anvaendning
FI925848A7 (fi) Tizolidinfoereningar, som innehaoller en kinogrupp, deras framstaellning och terapeutiska anvaendningar
FI922390L (fi) Initiatorsuspensioner, deras framstaellning och anvaendning